Hasta un 35% de sobreprecio habría pagado la Central de Abastecimiento del Sistema Nacional de Servicios de Salud (Cenabast), que intermedia la compra de medicamentos para consultorios y hospitales públicos. Ese fue uno de los puntos medulares del requerimiento de la Fiscalía Nacional Económica (FNE) en contra de los laboratorios Fresenius Kabi Chile, su filial Sanderson, y Biosano, por acordar un supuesto pacto para afectar el resultado de los concursos convocados entre 1999 y la primera mitad de 2013.
Featured News
Age-Restriction Laws Are Proliferating; So Too Are the Difficult Tradeoffs Policymakers Face
Dec 23, 2025 by
CPI
Federal AI Strategy Raises Compliance Stakes for Banks and Big Tech
Dec 23, 2025 by
CPI
Google Sues Alleged China-Based Hackers Over Widespread Phishing Scheme
Dec 22, 2025 by
CPI
Europe Moves to Clarify What Counts as Personal Data
Dec 22, 2025 by
CPI
Larry Ellison Offers $40 Billion Guarantee as Paramount Renews Bid for Warner Bros
Dec 22, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi